This content is for healthcare professionals only. Please confirm that you are a healthcare professional.AcceptDecline
touchCONGRESS Expert Interviews: Advanced Breast Cancer
Length of activity: 70 minutes Prof. Gabriel Hortobagyi, Prof. Joan Albanell, Prof. Sibylle Loibl, Prof. Mario Campone, Prof. Giuseppe Curigliano, and Prof. Stephen Johnston discuss the latest data from the (ESMO) Breast Cancer Congress 2019, and consider what the findings may mean for global and regional clinical practice.
THIS CONTENT IS AVAILABLE FOR FREE TO REGISTERED USERS You are not currently logged in. LOGIN or REGISTER to access this content
LOGIN or REGISTER to access this content
Immediate, and unrestricted free access to all resources
Earn AMA PRA Category 1 Credits™ for completing accredited activities
Bi-weekly scientific newsletters highlighting the latest emerging data and industry news
Access to your personalised learning profile and CME record.
Stay up to date with the latest developments in the treatment of solid tumours with our expert summary of what is expected at the ESMO Congress in Barcelona, Spain, 27 September–1 October 2019.
Dr Hendrik-Tobias Arkenau (Executive Medical Director of the Sarah Cannon Research Institute, London, UK), Prof. Dirk Jäger (Head of the Medical Oncology Department, University Hospital Heidelberg, Germany) and Prof. Eric Van Cutsem (Head of Clinical Digestive Oncology, KU Leuven, Belgium) review the most important challenges in treating solid tumours and how emerging data expected at the ESMO Congress 2019 could influence the future clinical management of solid tumours.
The information in this activity is intended for oncologists and other healthcare professionals involved in the treatment of patients diagnosed with solid tumours.
After watching this touchEXPERT OPINIONS, you should be able to:
Identify solid tumour types with the greatest unmet clinical need in terms of effective new therapy approaches
Discuss emerging data for new immunotherapies and targeted therapies in solid tumours and know how to identify patients that may benefit from these new treatments
Evaluate the rationales for different combination and sequential therapy approaches with new agents in solid tumours
Please feed back on these touchEXPERT OPINIONS on the following: (scale 1–5, 1 strongly disagree; 5 strongly agree).